Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the “3 + 7” induction regimen for acute myeloid leukemia
Yishai Ofran(Shaare Zedek Medical Center), Jacob M. Rowe(Technion – Israel Institute of Technology), Tsila Zuckerman(Johannes Gutenberg University Mainz), Netanel A. Horowitz(Rambam Health Care Campus), Shimrit Ringelstein(Technion – Israel Institute of Technology), Sharon Gino‐Moor(Bnai Zion Medical Center), Ariela Arad(Laniado Hospital), Ron Ram(Tel Aviv University), Ilana Hellmann(Meir Medical Center), Ronit Leiba(Rambam Health Care Campus), Revital Saban(Shaare Zedek Medical Center), Chezi Ganzel(Shaare Zedek Medical Center), Michal Hayun(Rambam Health Care Campus), Shlomo Bulvik(Laniado Hospital), Israel Henig(Rush University Medical Center), Moshe E. Gatt(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Ron Hoffman, Noa Lavi(Rambam Health Care Campus)
Cited by 29
Related Papers
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859